AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of AstraZeneca PLC (LON:AZN) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is £153.33.

Several research firms recently issued reports on AZN. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and set a £115 target price on shares of AstraZeneca in a research report on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating and set a £180 target price on shares of AstraZeneca in a research report on Wednesday, May 13th. Finally, Citigroup increased their target price on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research report on Friday, April 10th.

AstraZeneca Stock Performance

Shares of LON AZN opened at £137.12 on Monday. The firm has a fifty day moving average price of £142.43 and a 200-day moving average price of £141.42. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The stock has a market cap of £212.65 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 0.86 and a beta of 0.22. AstraZeneca has a 1 year low of £101.03 and a 1 year high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.